Novo Nordisk is actively involved in projects looking at stem cells
with other scientific leaders across the world. We are currently
focusing on the use of human pluripotent stem cells. Pluripotent stem
cells, which include human embryonic stem cells, are stem cells that
can form all other cell types in the body. In lab tests, these cells
are so far the only type of stem cell that can be used to make cells
that produce insulin.
Novo Nordisk, together with the majority of scientists within the field of stem cell research, believes it is essential to conduct research with pluripotent stem cells. This is because it is crucial to gain basic knowledge about how cells grow and develop to allow us to confirm the possibility of using stem cells in cell replacement therapies.
Novo Nordisk is at the forefront of stem cell research and since 2008 has had a research project focussing on the directed differentiation of pluripotent stem cells into beta cells that can produce insulin.
Novo Nordisk is also looking at how differentiated pluripotent stem cells may be used in other serious chronic diseases.